Side Effects·5 min read

Melanotan-1 Side Effects: Nausea and Mole Changes

Nausea hits early. Mole darkening is the watch-for. Full safety breakdown from afamelanotide trials and community data.

Save

Melanotan-1 / afamelanotide side effects across trial and community data

Melanotan-1 — afamelanotide — has the most complete clinical safety dataset of the melanotan peptides, anchored by Phase 3 trials in erythropoietic protoporphyria (EPP) that supported FDA and EMA approval. Cosmetic use of research-peptide melanotan-1 for tanning is not covered by those trials and is unapproved. The trial-grade adverse-event picture remains the most informative source for any user evaluating the molecule, but the EPP trial population is small and skin-disease-relevant — dose-conversion to cosmetic use is community-defined.

Research-context information only. Melanotan-1 (afamelanotide) is the active ingredient in FDA-approved products for erythropoietic protoporphyria; research-peptide and compounded forms for cosmetic tanning are not FDA-approved. Protocols, doses, and reactions reported below come from clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Trial-Reported Adverse Events

From the two EPP Phase 3 trials (Langendonk et al., PMID 26132941) using a 16 mg subcutaneous implant every 60 days (EU trial: 38 afamelanotide / 36 placebo; U.S. trial: 48 / 45):

Event Afamelanotide (EU / U.S.) Placebo (EU / U.S.)
Headache 34% / 40% 39% / 29%
Nausea 18% / 19% 17% / 18%
Implant-site discoloration 11% / 19% 0% / 0%
Pigmentation disorder 8% / 2% 0% / 0%
Melanocytic nevus 0% / 4% 0% / 2%
Fatigue 3% / 6% 6% / 0%
Early discontinuation (all causes) 4 of 38 / 3 of 48 2 of 36 / 4 of 45

The trial authors reported adverse events as mostly mild, with serious adverse events not considered drug-related. A long-term observational study of 115 EPP patients treated with 1,023 implants over up to 8 years recorded only minor adverse events attributable to afamelanotide, predominantly nausea (Biolcati et al., PMID 25494545).

The afamelanotide implant delivers a sustained pharmacologic dose over 60 days; research-peptide cosmetic use is typically a daily subcutaneous injection at lower per-dose mass. The exposure pattern differs substantially.

CategoryTanning Peptides
Classmelanocortin agonist
GoalSkin & Hair
Melanotan 1 research kit
Best Kit Deal10-VialCOASave 32%

Glacier Aminos — 10mg × 10 (100mg) — $191 $172 with code thepeptidecatalog (10% off) ($1.72/mg)

Top Melanotan I Vendors

Ranked by price, COA availability, and reputation

1
Ascension PeptidesCOA
10/10
10mg$5.00/mg
2
Ion PeptideCOA
9.7/10
10mg$3.50/mg
3
Glacier AminosCOA
9.3/10
10mg$2.55/mg
See full vendor rankings for Melanotan I →

Pigmentary Changes Are the Defining Trial Finding

Trial-reported pigmentary changes include:

  • Diffuse skin darkening — the expected pharmacologic effect; the trial authors noted that increased pigmentation partially unblinded the Phase 3 trials (Langendonk et al., PMID 26132941).
  • Darkening of existing nevi — reported in a few afamelanotide-treated patients.
  • Appearance of new pigmented lesions — documented; annual dermatologic surveillance is part of the EU EPP treatment program.

The melanoma question has been addressed across multiple post-marketing surveillance reports for SCENESSE (the approved product). The published surveillance data has not identified an increased melanoma rate in the small EPP-treated population. Dermatologic monitoring remains mandatory in the EU treatment program.

For users using research-peptide melanotan-1 cosmetically, that dermatologic surveillance is typically absent — which community sources flag as the most significant gap between research-peptide use and the trial-validated use pattern.

Melanotan-1 trial adverse event chart

Self-Reported Community Adverse Events for Cosmetic Use

Note on labeling: the events below come from r/peptides, r/melanotan, and community sources for research-peptide melanotan-1 used for cosmetic tanning. They overlap with trial findings but reflect a different exposure pattern (lower per-dose, daily, longer duration).

Nausea after early injections

Community sources commonly describe nausea in the first 1-7 days of subcutaneous dosing, often most severe within 2 hours of injection. Self-reported community sources commonly describe starting at very low doses (10-25% of the typical maintenance dose) and slowly titrating upward to reduce this.

Facial flushing within 30 minutes

Self-reported community timelines describe brief warmth and visible flush during the first 30-60 minutes after injection, fading without intervention.

Increased appetite

Community reports cluster around modestly increased appetite, attributed by community sources to the MC4 receptor activation that also drives the melanocortin family's hunger effects. The pattern is less pronounced than melanotan-2 in community reports.

Mole and pigmentation changes

The community-reported pigmentary pattern aligns with trial findings: diffuse skin darkening is the targeted effect; community sources commonly describe new freckles and darkening of existing moles. Community sources also commonly describe annual full-body dermatologic exams as the appropriate monitoring response — though many users don't do them.

Fatigue and headache

The most consistent community feedback for the first week is brief headache and mild fatigue, fading within 7-10 days.

Less Common but Notable Events

  • Sexual side effects — less common than with melanotan-2 (which acts at MC4 more strongly). Sparse community reports of altered libido at higher doses.
  • Yawning/stretching reflex — documented mechanism finding for melanocortin agonists; sparse in community reports.
  • Allergic-type reactions — rare in trials and community sources.

Dose-Response Patterns

Trial dosing — 16 mg implant every 60 days — produces a pharmacologic plateau, not the pulsatile exposure of daily injections. Community-reported research-peptide dosing typically uses 0.5-1 mg subcutaneous daily during loading (1-2 weeks), then 0.5-1 mg 2-3x weekly for maintenance. Self-reported community sources describe:

  • Nausea more pronounced during loading.
  • Pigmentary effects scaling with cumulative dose, not per-injection dose.
  • Mole changes appearing in users with multiple loading cycles.
Bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Shop bac water made for peptides

Dose-Pause and Discontinuation Patterns

Trial protocols paused dosing for protocol-defined adverse events. Community sources commonly describe stopping immediately and consulting a dermatologist when new pigmented lesions appear that look atypical. Pause-and-resume for nausea or GI events is uncommon in community reports for melanotan-1 (less common than for melanotan-2).

The most-cited community trigger for permanent discontinuation: dermatologist flagging a mole as needing biopsy or removal.

Melanotan-1 dermatologic monitoring map

Core Supplies for This Protocol

The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.

Cooluli Classic 4L Mini Fridge
Storage

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

View on Amazon →
BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)
Injection

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

View on Amazon →
Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped
Injection

Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped

Medical-grade 70% isopropyl alcohol prep pads, individually wrapped and sterile single-use. Standard for cleaning vial stoppers and injection sites before sub-Q dosing.

View on Amazon →
CONTOUR NEXT GEN Glucose Meter All-In-One Kit
Tracking

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

View on Amazon →

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

Full catalog →

Frequently Asked Questions

What side effects do melanotan-1 / afamelanotide trials report?
Phase 3 trials of afamelanotide for erythropoietic protoporphyria reported headache (34-40% on afamelanotide vs 29-39% on placebo), nausea (18-19% vs 17-18%), nasopharyngitis, and back pain as the most common adverse events, with no clinically relevant between-group differences apart from implant-site hyperpigmentation in about one third of afamelanotide patients and moles that darkened in a few (Langendonk et al., PMID 26132941).
Does melanotan-1 darken moles?
Yes. Trial reports and dermatologic case-series describe darkening of existing nevi and appearance of new pigmented lesions during afamelanotide treatment. Annual dermatologic monitoring is standard in the EU EPP treatment guidelines. Sources describe community use as accepting this as a known consequence of melanocyte activation.
Is melanotan-1 the same as melanotan-2?
No. Melanotan-1 (afamelanotide) is a more selective α-MSH analog with FDA and EMA approval for erythropoietic protoporphyria under the brand name SCENESSE. Melanotan-2 is unapproved everywhere and has a different receptor-binding profile and a different (worse) adverse-event picture (see [melanotan-2 side effects](/articles/melanotan-2-side-effects)).
Can melanotan-1 cause melanoma?
Published clinical trial data did not identify increased melanoma rates in the EPP population. The theoretical mechanism — sustained melanocyte activation — has been a long-standing concern, and the EU EPP treatment program includes mandatory annual dermatologic surveillance for this reason. Community use without that surveillance is a higher-risk pattern.
When do users describe stopping melanotan-1?
Trial protocols paused dosing for protocol-defined adverse events. Community sources commonly describe stopping when new pigmented lesions appear, when a dermatologist flags an existing lesion as needing biopsy, or when GI side effects persist.

References

Citation Topic PMID
Langendonk et al., N Engl J Med (2015) Afamelanotide Phase 3 in erythropoietic protoporphyria 26132941
Biolcati et al., Br J Dermatol (2015) Long-term observational study of afamelanotide in 115 EPP patients 25494545

For educational and research purposes only. This is not medical advice. Research-peptide melanotan-1 used for cosmetic tanning is not FDA-approved. Consult a healthcare provider before use.